After a quarter-century at the helm of the Dolder Group, Dr. Matthys Dolder has handed the company’s operations management over to Bruno Crippa as the new CEO. Fifth-generation Dr. Patrick Dolder has joined the Board of Directors. The appointments are in effect as of January 1, 2020.

Bruno Crippa is a chemist by education and has been with the Dolder Group for over ten years. He has held the position of Business Unit Manager, Specialty Chemicals and Head of our subsidiaries in Italy, Turkey, and Spain. He is now also a shareholder. 

Dr. Patrick Dolder holds a PhD in pharmacy and will certainly contribute new ideas to shape the future development of our enterprise.

Dr. Matthys Dolder continues to serve the Group as Chairman of the Board.

Continuity is important to our family business, which was established in 1898. These changes are a sign of evolution and guarantee that DOLDER will remain a reliable business partner.

After all, Dolder means value.